RBF Capital’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

RBF Capital’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-70,171	Closed	-$674K	–	618
2024 Q4	$674K	Hold	70,171	–	–	0.03%	344
2024 Q3	$201K	Hold	70,171	–	–	0.01%	548
2024 Q2	$205K	Hold	70,171	–	–	0.01%	518
2024 Q1	$224K	Hold	70,171	–	–	0.01%	497
2023 Q4	$236K	Hold	70,171	–	–	0.01%	475
2023 Q3	$167K	Hold	70,171	–	–	0.01%	484
2023 Q2	$124K	Hold	70,171	–	–	0.01%	492
2023 Q1	$216K	Hold	70,171	–	–	0.02%	441
2022 Q4	$372K	Hold	70,171	–	–	0.03%	385
2022 Q3	$248K	Hold	70,171	–	–	0.02%	437
2022 Q2	$181K	Buy	+70,171	New	+$195K	0.01%	467

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

RBF Capital's PSTX Position: Q1 2025 in Review

RBF Capital sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 70,171 shares — an estimated $674K sold.

RBF Capital first reported a position in PSTX in Q2 2022 and held it in 11 quarters. The position peaked at $674K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

RBF Capital reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
RBF Capital sold 70,171 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $674K.
RBF Capital first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2022 and held it in 11 quarters.
RBF Capital's Poseida Therapeutics, Inc. Common Stock position peaked at $674K in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on RBF Capital's 13F filing for Q1 2025, filed 15 May 2025.